About Portola Pharmaceuticals (NASDAQ:PTLA)
Portola Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company's two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots. Its third product candidate is Cerdulatinib. The Company's Syk is a mediator of immune response in various types of immune cells. The Company has a program of selective Syk inhibitors, one of which is partnered with Ora Inc. Betrixaban is an oral once-daily inhibitor of Factor Xa in development for extended duration venous thromboembolism (VTE) prophylaxis in acute medically ill patients. Andexanet alfa is an orphan drug, which is a recombinant protein designed to reverse anticoagulant activity in patients treated with an fXa inhibitor.
Industry, Sector and Symbol
Trailing P/E Ratio-6.39539748953975
Forward P/E Ratio-6.45
Sales & Book Value
Annual Sales$22.55 million
Price / Sales88.65
Price / CashN/A
Book Value$5.36 per share
Price / Book5.70
Return on Equity-108.43%
Return on Assets-61.83%
Portola Pharmaceuticals (NASDAQ:PTLA) Frequently Asked Questions
What is Portola Pharmaceuticals' stock symbol?
Portola Pharmaceuticals trades on the NASDAQ under the ticker symbol "PTLA."
How were Portola Pharmaceuticals' earnings last quarter?
Portola Pharmaceuticals Inc (NASDAQ:PTLA) issued its earnings results on Wednesday, February, 28th. The biopharmaceutical company reported ($1.41) EPS for the quarter, beating analysts' consensus estimates of ($1.46) by $0.05. The biopharmaceutical company had revenue of $9.80 million for the quarter, compared to the consensus estimate of $3.71 million. Portola Pharmaceuticals had a negative return on equity of 108.43% and a negative net margin of 1,268.34%. The business's quarterly revenue was down 28.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.95) earnings per share. View Portola Pharmaceuticals' Earnings History.
When will Portola Pharmaceuticals make its next earnings announcement?
Where is Portola Pharmaceuticals' stock going? Where will Portola Pharmaceuticals' stock price be in 2018?
7 brokers have issued twelve-month target prices for Portola Pharmaceuticals' stock. Their predictions range from $49.00 to $75.00. On average, they anticipate Portola Pharmaceuticals' stock price to reach $66.67 in the next twelve months. View Analyst Ratings for Portola Pharmaceuticals.
Who are some of Portola Pharmaceuticals' key competitors?
Some companies that are related to Portola Pharmaceuticals include FibroGen (FGEN), ABLYNX (ABLYF), Taro Pharmaceutical Industries (TARO), Hikma Pharmaceutic (HKMPF), Advanced Accelerator Application (AAAP), Loxo Oncology (LOXO), Ligand Pharmaceuticals (LGND), Array Biopharma (ARRY), TESARO (TSRO), ACADIA Pharmaceuticals (ACAD), Halozyme Therapeutics (HALO), Clovis Oncology (CLVS), Evotec (EVTCY), China Biologic Products (CBPO), Puma Biotechnology (PBYI), Ascendis Pharma A/S (ASND), Amicus Therapeutics (FOLD) and Emergent Biosolutions (EBS).
Who are Portola Pharmaceuticals' key executives?
Portola Pharmaceuticals' management team includes the folowing people:
- Hollings C. Renton III, IndependentChairman of the Board (Age 70)
- William Lis, Chief Executive Officer, Director (Age 52)
- Mardi C. Dier, Chief Financial Officer, Executive Vice President (Age 53)
- John B. Moriarty J.D., Executive Vice President, General Counsel (Age 50)
- John T. Curnutte M.D. Ph.D., Executive Vice President - Research & Development (Age 65)
- Tao Fu, Executive Vice President, Chief Commercial and Business officer (Age 45)
- John Lawrence, Senior Vice President, Chief Medical Officer
- Jeffrey W. Bird M.D. Ph.D., Independent Director (Age 56)
- Laura A. Brege, Independent Director (Age 59)
- Dennis M. Fenton Ph.D., Independent Director (Age 65)
Has Portola Pharmaceuticals been receiving favorable news coverage?
News headlines about PTLA stock have trended somewhat positive on Saturday, Accern Sentiment Analysis reports. The research firm ranks the sentiment of press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Portola Pharmaceuticals earned a coverage optimism score of 0.17 on Accern's scale. They also assigned media coverage about the biopharmaceutical company an impact score of 44.86 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.
Who are Portola Pharmaceuticals' major shareholders?
Portola Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.20%), Kornitzer Capital Management Inc. KS (1.27%), Fred Alger Management Inc. (1.16%), Wells Fargo & Company MN (1.05%), Deutsche Bank AG (0.97%) and Geode Capital Management LLC (0.95%). Company insiders that own Portola Pharmaceuticals stock include (Mauritius) Pte Ltd Maxwell, Charles J Homcy, Henry Ward Wolff, Jeffrey W Bird, John T Curnutte, Mardi Dier, Tao Fu and William Lis. View Institutional Ownership Trends for Portola Pharmaceuticals.
Which major investors are selling Portola Pharmaceuticals stock?
PTLA stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Renaissance Technologies LLC, Two Sigma Investments LP, Guggenheim Capital LLC, Pinnacle Associates Ltd., Marcus Capital LLC, Alliancebernstein L.P. and Metropolitan Life Insurance Co. NY. Company insiders that have sold Portola Pharmaceuticals company stock in the last year include (Mauritius) Pte Ltd Maxwell, Charles J Homcy, Henry Ward Wolff, John T Curnutte, Mardi Dier, Tao Fu and William Lis. View Insider Buying and Selling for Portola Pharmaceuticals.
Which major investors are buying Portola Pharmaceuticals stock?
PTLA stock was bought by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, BlackRock Inc., Two Sigma Advisers LP, Artal Group S.A., Amundi Pioneer Asset Management Inc., Kornitzer Capital Management Inc. KS, UBS Asset Management Americas Inc. and GW&K Investment Management LLC. View Insider Buying and Selling for Portola Pharmaceuticals.
How do I buy shares of Portola Pharmaceuticals?
Shares of PTLA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Portola Pharmaceuticals' stock price today?
One share of PTLA stock can currently be purchased for approximately $30.57.
How big of a company is Portola Pharmaceuticals?
Portola Pharmaceuticals has a market capitalization of $2.07 billion and generates $22.55 million in revenue each year. The biopharmaceutical company earns $-286,090,000.00 in net income (profit) each year or ($4.78) on an earnings per share basis. Portola Pharmaceuticals employs 252 workers across the globe.
How can I contact Portola Pharmaceuticals?
Portola Pharmaceuticals' mailing address is 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-246-7000 or via email at [email protected]
MarketBeat Community Rating for Portola Pharmaceuticals (PTLA)MarketBeat's community ratings are surveys of what our community members think about Portola Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Portola Pharmaceuticals (NASDAQ:PTLA) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Buy|
|Consensus Rating Score: ||2.86||3.00||3.00||2.88|
|Ratings Breakdown: ||0 Sell Rating(s)|
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$66.67||$68.17||$75.67||$65.83|
|Price Target Upside: ||118.08% upside||51.79% upside||48.40% upside||10.66% upside|
Portola Pharmaceuticals (NASDAQ:PTLA) Consensus Price Target History
Portola Pharmaceuticals (NASDAQ:PTLA) Analyst Ratings History
(Data available from 3/24/2016 forward)
Portola Pharmaceuticals (NASDAQ:PTLA) Earnings History and Estimates Chart
Portola Pharmaceuticals (NASDAQ PTLA) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|2/28/2018||Q4 2017||($1.46)||($1.41)||$3.71 million||$9.80 million||View||Listen|
|11/6/2017||Q3 2017||($1.49)||($1.41)||$4.71 million||$3.83 million||View||N/A|
|8/9/2017||Q2 2017||($1.10)||($1.22)||$4.28 million||$3.79 million||View||Listen|
|5/8/2017||Q1 2017||($1.20)||($0.74)||$4.21 million||$5.12 million||View||Listen|
|2/28/2017||Q4 2016||($1.12)||($0.95)||$3.98 million||$13.70 million||View||Listen|
|11/7/2016||Q3||($1.10)||($1.64)||$4.10 million||$9.30 million||View||Listen|
|8/9/2016||Q216||($1.20)||($1.02)||$4.38 million||$4.23 million||View||Listen|
|5/5/2016||Q1||($1.06)||($1.15)||$7.91 million||$8.30 million||View||Listen|
|2/26/2016||Q415||($1.12)||($1.23)||$2.43 million||$4.40 million||View||Listen|
|11/9/2015||Q3 2015||($1.24)||($1.05)||$2.40 million||$2.91 million||View||N/A|
|8/4/2015||Q215||($1.07)||($1.12)||$2.30 million||$2.39 million||View||Listen|
|5/6/2015||Q115||($1.09)||($0.95)||$2.60 million||$2.36 million||View||Listen|
|3/2/2015||Q414||($0.90)||($0.82)||$2.40 million||$2.41 million||View||Listen|
|11/10/2014||Q314||($0.92)||($0.86)||$2.73 million||$2.40 million||View||Listen|
|8/6/2014||Q214||($0.79)||($0.76)||$2.44 million||$2.42 billion||View||Listen|
|5/12/2014||Q114||($0.72)||($0.75)||$1.81 million||$2.40 million||View||Listen|
|2/27/2014||Q4||($0.57)||($0.63)||$2.17 million||$2.10 million||View||Listen|
|11/5/2013||Q3 2013||($0.68)||($0.53)||$2.00 million||$2.77 million||View||N/A|
|8/15/2013||($0.72)||($1.47)||$2.00 million||$2.60 million||View||Listen|
Portola Pharmaceuticals (NASDAQ:PTLA) Earnings Estimates
2018 EPS Consensus Estimate: ($4.49)
2019 EPS Consensus Estimate: ($0.59)
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Portola Pharmaceuticals (NASDAQ:PTLA)
No dividend announcements for this company have been tracked by MarketBeat.com
Portola Pharmaceuticals (NASDAQ PTLA) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 5.50%
Institutional Ownership Percentage: 88.43%
Portola Pharmaceuticals (NASDAQ PTLA) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|3/12/2018||Tao Fu||EVP||Sell||1,135||$38.47||$43,663.45||18,346|| |
|12/15/2017||Henry Ward Wolff||Director||Sell||12,000||$47.00||$564,000.00|| |
|7/18/2017||John T. Curnutte||Insider||Sell||10,000||$65.00||$650,000.00|| |
|7/18/2017||Tao Fu||EVP||Sell||5,812||$65.00||$377,780.00|| |
|7/11/2017||Mardi Dier||VP||Sell||23,350||$60.00||$1,401,000.00|| |
|6/28/2017||William Lis||CEO||Sell||269,299||$55.43||$14,927,243.57|| |
|6/27/2017||Mardi Dier||VP||Sell||93,392||$55.46||$5,179,520.32|| |
|6/26/2017||John T. Curnutte||Insider||Sell||60,000||$57.88||$3,472,800.00|| |
|6/26/2017||Tao Fu||EVP||Sell||7,000||$57.14||$399,980.00|| |
|6/23/2017||Charles J. Homcy||Director||Sell||120,803||$53.06||$6,409,807.18|| |
|6/1/2017||(Mauritius) Pte Ltd Maxwell||Major Shareholder||Sell||1,700,000||$34.40||$58,480,000.00|| |
|6/1/2017||Jeffrey W Bird||Director||Buy||119,442||$31.85||$3,804,227.70||3,000|| |
|4/11/2017||William Lis||CEO||Sell||6,750||$36.06||$243,405.00||4,730|| |
|4/10/2017||Tao Fu||EVP||Sell||1,097||$36.97||$40,556.09|| |
|3/15/2017||Charles J. Homcy||Director||Sell||50,000||$40.06||$2,003,000.00|| |
|3/15/2017||Mardi Dier||VP||Sell||10,235||$40.02||$409,604.70|| |
|5/2/2016||William Lis||CEO||Sell||5,675||$23.86||$135,405.50||18,333|| |
|12/9/2015||Fullerton Management Pte Ltd||Major Shareholder||Buy||750,000||$48.00||$36,000,000.00|| |
|9/18/2015||Charles J. Homcy||Director||Sell||40,067||$56.25||$2,253,768.75|| |
|9/18/2015||Mardi Dier||CFO||Sell||8,912||$55.00||$490,160.00|| |
|7/15/2015||John T Curnutte||EVP||Sell||10,000||$50.00||$500,000.00|| |
|7/15/2015||William Lis||CEO||Sell||50,000||$50.00||$2,500,000.00|| |
|7/13/2015||Charles J Homcy||Director||Sell||50,000||$48.00||$2,400,000.00|| |
|7/2/2015||William Lis||CEO||Sell||15,000||$45.60||$684,000.00|| |
|7/1/2015||William Lis||CEO||Sell||30,000||$45.01||$1,350,300.00|| |
|6/30/2015||William Lis||CEO||Sell||15,000||$44.48||$667,200.00|| |
|6/29/2015||Charles J Homcy||Director||Sell||100,000||$43.78||$4,378,000.00|| |
|6/22/2015||John T Curnutte||EVP||Sell||10,000||$47.50||$475,000.00|| |
|6/16/2015||John T Curnutte||EVP||Sell||10,000||$45.00||$450,000.00|| |
|6/8/2015||Mardi Dier||CFO||Sell||16,119||$43.00||$693,117.00|| |
|5/29/2015||John T Curnutte||EVP||Sell||10,000||$42.50||$425,000.00|| |
|5/28/2015||John T Curnutte||EVP||Sell||10,000||$40.30||$403,000.00|| |
|5/27/2015||Mardi Dier||CFO||Sell||6,076||$41.00||$249,116.00|| |
|5/12/2015||Mardi Dier||CFO||Sell||13,290||$37.88||$503,425.20|| |
|5/11/2015||Hollings Renton||Director||Sell||10,520||$38.33||$403,231.60|| |
|5/11/2015||Mardi Dier||CFO||Sell||13,674||$38.21||$522,483.54|| |
|4/30/2015||William Lis||CEO||Sell||45,000||$35.60||$1,602,000.00|| |
|2/23/2015||Charles J Homcy||Director||Sell||20,000||$40.00||$800,000.00|| |
|2/23/2015||John T Curnutte||EVP||Sell||10,000||$40.00||$400,000.00|| |
|2/23/2015||Mardi Dier||CFO||Sell||5,692||$39.95||$227,395.40|| |
|2/18/2015||John T Curnutte||EVP||Sell||10,000||$37.50||$375,000.00|| |
|2/17/2015||Charles J Homcy||Director||Sell||20,000||$36.00||$720,000.00|| |
|2/17/2015||John T Curnutte||EVP||Sell||10,000||$35.00||$350,000.00|| |
|2/13/2015||Charles J Homcy||Director||Sell||20,000||$34.05||$681,000.00|| |
|2/13/2015||John T Curnutte||EVP||Sell||10,000||$32.50||$325,000.00|| |
|1/28/2015||Charles J Homcy||Director||Sell||19,700||$30.00||$591,000.00|| |
|1/20/2015||William Lis||CEO||Sell||20,000||$27.32||$546,400.00|| |
|1/16/2015||William Lis||CEO||Sell||20,000||$26.94||$538,800.00|| |
|11/25/2014||Mardi Dier||CFO||Sell||1,118||$28.23||$31,561.14|| |
|11/20/2014||William Lis||CEO||Sell||40,000||$26.95||$1,078,000.00|| |
|11/17/2014||William Lis||CEO||Sell||30,000||$26.69||$800,700.00|| |
|10/8/2014||(Mauritius) Pte Ltd Maxwell||Major Shareholder||Buy||1,600,000||$26.00||$41,600,000.00|| |
|8/25/2014||Mardi Dier||CFO||Sell||5,000||$26.26||$131,300.00|| |
|7/25/2014||Mardi Dier||CFO||Sell||5,000||$24.11||$120,550.00|| |
|7/3/2014||William Lis||CEO||Sell||30,000||$30.41||$912,300.00|| |
|6/30/2014||William Lis||CEO||Sell||10,000||$29.23||$292,300.00|| |
|6/25/2014||Mardi Dier||CFO||Sell||5,000||$28.52||$142,600.00|| |
|6/18/2014||John T Curnutte||EVP||Sell||30,000||$28.33||$849,900.00|| |
|6/18/2014||Mardi Dier||CFO||Sell||3,706||$29.95||$110,994.70|| |
|6/16/2014||John T Curnutte||EVP||Sell||10,000||$26.00||$260,000.00|| |
|6/10/2014||Nicholas Galakatos||Director||Sell||1,369||$23.36||$31,979.84|| |
|5/29/2014||Mardi Dier||CFO||Sell||5,000||$23.00||$115,000.00|| |
|5/27/2014||William Lis||CEO||Sell||30,000||$20.83||$624,900.00|| |
|5/21/2014||William Lis||CEO||Sell||10,000||$19.87||$198,700.00|| |
|5/16/2014||Jean Jacques Bienaime||Director||Sell||1,000||$22.03||$22,030.00||706|| |
|4/25/2014||Mardi Dier||CFO||Sell||5,000||$24.14||$120,700.00||24,824|| |
|3/25/2014||Mardi Dier||CFO||Sell||5,000||$25.69||$128,450.00||29,824|| |
|10/22/2013||Charles J Homcy||Director||Sell||95,962||$23.75||$2,279,097.50|| |
|5/28/2013||(Mauritius) Pte Ltd Maxwell||Major Shareholder||Buy||700,000||$14.50||$10,150,000.00|| |
Portola Pharmaceuticals (NASDAQ PTLA) News Headlines
Portola Pharmaceuticals (NASDAQ:PTLA) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Portola Pharmaceuticals (NASDAQ:PTLA) Income Statement, Balance Sheet and Cash Flow Statement
Portola Pharmaceuticals (NASDAQ PTLA) Stock Chart for Saturday, March, 24, 2018